Board Member: James is a leading practitioner in the provision of corporate advisory services. James specialises in capital markets and merger and acquisition (M&A) issues, and has nearly 25 years’ experience in equity and hybrid capital raisings, corporate finance transactions, and public and private M&A dealings. Equipped with a strong reputation as a strategic adviser to company boards, independent directors and government bodies, James takes a commercial and practical approach to advising his clients in complex corporate matters. James’ advisory roles includes corporate governance issues, Corporations Act and stock exchange listing requirements and regulatory reviews He also draws heavily on a previous lengthy in-house secondment as general counsel of Minara Resources (formerly Anaconda Nickel). James is also recognised as a leading lawyer in the biosciences, pharmaceuticals industries and retirement living and aged care sectors. He provides both corporate advisory expertise and leads transactions in venture capital, capital markets and pre-IPO fundraising, IPOs, post-listing capital raisings, commercialisation and mergers and acquisitions.
James is also a standing guest lecturer for the University of Melbourne, Melbourne MBA program in the Mergers & Acquisitions course.
His career highlights include handling $888 million underwritten placement and pro rata accelerated non-renounceable entitlement offer for Mayne Pharma and helping establish the Victorian Life Sciences Computation Initiative for the University of Melbourne. He is also the primary legal adviser to Australia’s largest life sciences and medical technology fund, the Medical Research Commercialisation Fund, managed by Brandon Capital Partners Limited. He acted in relation to the sale of Spinifex to Swiss-based pharmaceutical giant Novartis for Spinifex Pharmaceuticals Pty Ltd and its major shareholder Brandon Capital.
James has also acted in relation to Fibrotech Therapeutics Pty Ltd, which is the largest ever early stage venture capital life sciences exit in Australia, sold to Shire Pharmaceuticals, Inc.
Other career highlights:
Australian Unity Limited – On its Carlton Aged Care Facility, Rathdowne Place Retirement Village, stage 2 of the Lifestyle Manor retirement village in Bondi, New South Wales and its Campbell Place Retirement Village and aged care facility.
QANTM Intellectual Property Limited – advised in relation to its initial public offering and listing on the Australian Securities Exchange, which included a restructure of the Davies Collison Cave and FPA Patent Attorneys partnerships in connection with listing.
Education Australia Limited – advised on $660 million initial public offering of IDP Education Australia Limited
Healthscope Limited – acted in relation to a notes offering and ASX listing.
Bionic Vision Australia – acted for a consortium comprising the University of New South Wales, the University of Melbourne, CSIRO, the Centre for Eye Research Australia and the Bionics Institute on the establishment of Bionic Vision Australia.
Beingmate Baby & Child Food Co Ltd – advised a leading Chinese infant food manufacturer, on its proposed alliance with New Zealand dairy co-operative Fonterra Co-operative Group, designed to help meet China’s growing demand for infant formula. The alliance is intended to create an integrated global supply chain from the farm gate direct to China’s consumers, using Fonterra’s milk pools and manufacturing sites.